What is the average price target for GUARDANT HEALTH INC (GH) stock?
34 analysts have analysed GH and the average price target is 132.26 USD. This implies a price increase of 68.28% is expected in the next year compared to the current price of 78.6.
GUARDANT HEALTH INC (GH) Forecast, Price Target & Analyst Ratings
NASDAQ:GH • US40131M1099
Current stock price
78.6 USD
-8.57 (-9.83%)
At close:
77.5 USD
-1.1 (-1.4%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GUARDANT HEALTH INC (GH).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.78
- Revenue Estimate
- 288.12M
Price Target Details & History
Consensus Price Target and Range
Mean target
$132.26
Upside
+ 68.28%
From current price of $78.60 to mean target of $132.26, Based on 34 analyst forecasts
Low
$64.07
Median
$132.60
High
$189.00
Price Target Revisions
1 Month
0.34%
3 Months
21.18%
Price Target Summary
34 Wall Street analysts provided a forecast for the next 12 months for GH. The average price target is 132.26 USD. This implies a price increase of 68.28% is expected in the next year compared to the current price of 78.6.
The average price target has been revised upward by 21.18% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.88%
GH was analyzed by 34 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about GH.
In the previous month the buy percentage consensus was at a similar level.
GH was analyzed by 34 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-06 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-24 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-20 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-20 | BTIG | Maintains | Buy -> Buy |
| 2026-02-20 | Stifel | Maintains | Buy -> Buy |
| 2026-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-20 | Evercore ISI Group | Maintains | In-Line -> In-Line |
| 2026-02-20 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-20 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-20 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-17 | Baird | Initiate | Outperform |
| 2026-01-26 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-09 | Stifel | Maintains | Buy -> Buy |
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-05 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2025-12-22 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-12-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-15 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-15 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-15 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-12 | BTIG | Maintains | Buy -> Buy |
| 2025-12-11 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 30, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.78
- Revenue Estimate
- 288.12M
- Revenue Q2Q
- 41.60%
- EPS Q2Q
- 4.54%
- Number of Analysts
- 26
Next Earnings Revisions
Revenue (1 Month)
-0.03%
Revenue (3 Months)
2.94%
EPS (1 Month)
2.56%
EPS (3 Months)
-17.83%
Next Earnings Summary
GH is expected to report earnings on 4/30/2026. The consensus EPS estimate for the next earnings is -0.78 USD and the consensus revenue estimate is 288.12M USD.
The next earnings revenue estimate has been revised upward by 2.94% in the past 3 months.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 563.948M 25.46% | 739.016M 31.04% | 982.021M 32.88% | 1.309B 33.30% | 1.678B 28.19% | 2.121B 26.40% | 2.699B 27.25% | 3.293B 22.01% | 3.606B 9.51% | 4.255B 18.00% | 4.936B 16.00% | |
| EBITDA YoY % growth | -521.844M -2.64% | -401.207M 23.12% | -397.512M 0.92% | -186.204M 53.16% | -63.626M 65.83% | 155.83M 344.92% | 538.69M 245.69% | 668.02M 24.01% | 1.07B 60.17% | 1.158B 8.22% | 1.214B 4.84% | |
| EBIT YoY % growth | -564.725M -3.73% | -443.594M 21.45% | -437.248M 1.43% | -350.973M 19.73% | -253.475M 27.78% | -14.424M 94.31% | 126.82M 979.21% | 487.72M 284.58% | 716.57M 46.92% | 995.7M 38.95% | 1.223B 22.83% | |
| Operating Margin | -100.14% | -60.02% | -44.53% | -26.81% | -15.11% | -0.68% | 4.70% | 14.81% | 19.87% | 23.40% | 24.78% | |
| EPS YoY % growth | -3.34 36.33% | -3.56 -6.59% | -3.36 5.62% | -2.89 13.91% | -1.97 32.05% | -0.44 77.87% | 2.61 699.77% | 4.02 54.15% | 6.57 63.38% | 7.31 11.29% | 7.95 8.73% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.78 4.54% | -0.74 7.53% | -0.67 10.03% | -0.70 30.15% | -0.65 16.94% | -0.55 24.98% | -0.42 36.37% | -0.38 46.00% | -0.23 64.09% | -0.03 95.05% | 0.23 154.31% | 0.25 166.44% |
| Revenue Q2Q % growth | 288.12M 41.60% | 315.32M 35.86% | 341.72M 28.86% | 364.31M 29.53% | 372.83M 29.40% | 406.44M 28.90% | 436.75M 27.81% | 462.4M 26.92% | 468.06M 25.54% | 517.39M 27.30% | 568.07M 30.07% | 596.97M 29.10% |
| EBITDA Q2Q % growth | -50.441M 49.96% | -44.545M 48.28% | -36.969M 46.66% | -40.593M 49.93% | -23.029M 54.34% | -13.75M 69.13% | -4.301M 88.37% | 4.52M 111.13% | 25.132M 209.13% | 78.28M 669.32% | 132.77M 3,187.05% | 146.98M 3,151.77% |
| EBIT Q2Q % growth | -103.732M 6.58% | -97.42M 8.45% | -87.955M 11.15% | -84.967M 29.67% | -89.105M 14.10% | -75.351M 22.65% | -58.725M 33.23% | -48.837M 42.52% | -36.318M 59.24% | 4.97M 106.60% | 43.77M 174.53% | 63.227M 229.47% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.21%
EPS Next 5 Year
26.17%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
28.48%
Revenue Next 5 Year
26.92%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
33.79%
EBIT Next 5 Year
29.86%
GUARDANT HEALTH INC / GH Forecast FAQ
Can you provide the upcoming earnings date for GUARDANT HEALTH INC?
GUARDANT HEALTH INC (GH) will report earnings on 2026-04-30, after the market close.
Can you provide the consensus estimates for GUARDANT HEALTH INC next earnings?
The consensus EPS estimate for the next earnings of GUARDANT HEALTH INC (GH) is -0.78 USD and the consensus revenue estimate is 288.12M USD.
How do analysts rate GUARDANT HEALTH INC (GH)?
The consensus rating for GUARDANT HEALTH INC (GH) is 85.8824 / 100 . This indicates that analysts generally have a positive outlook on the stock.